Transplantation of myoblast sheets is a promising therapy for enhancing cardiac function after heart failure. We have previously demonstrated that a 7-amino-acid sequence (Ser-Val-Val-Tyr-Gly-Leu-Arg) derived from osteopontin (SV peptide) induces angiogenesis. In this study, we evaluated the long-term therapeutic effects of myoblast sheets secreting SV in a rat infarction model.
Introduction
In heart failure, tissue damage processes caused by ischaemia, such as cell death, fibrosis, and hypertrophy, gradually progress until the cardiac tissue becomes dysfunctional. 1 -3 Transplantation of myoblast sheets is a promising treatment for ischaemic heart failure, and can inhibit left ventricular (LV) remodelling and improve cardiac function via paracrine effectors. 4 -8 The cell-sheet technique avoids the arrhythmogenicity associated with skeletal myoblast therapy by injection. 9 However, this treatment has failed to achieve long-term therapeutic effects, because the transplanted sheets are exposed to blood and nutrient deprivation and drop out from the injured myocardium. Recent studies demonstrated that myoblast sheets that overexpress different cardioprotective agents display enhanced therapeutic effects. 10, 11 Therefore, the combined application of gene therapy with angiogenic agents and myoblast sheet transplantation may achieve sustained therapeutic efficacy. Through the secretion of angiogenic factors from transplanted myoblasts, the newly formed blood vessels can supply blood flow to the surviving myocardium and the transplanted cells, and the functional deterioration of ischaemic cardiomyopathy should thus improve in the long term.
Osteopontin is a multifunctional cytokine expressed during healing and fibrotic processes. 12 We have previously reported that the osteopontinderived peptide Ser-Val-Val-Tyr-Gly-Leu-Arg (SVVYGLR; SV) exhibits angiogenic activity in vitro and in vivo, 13 -17 and that its angiogenic activity is as potent as that of vascular endothelial growth factor (VEGF). 14 Owing to their high molecular weights, the most well-known angiogenesis-promoting factors, namely, VEGF and hepatocyte growth factor (HGF), are resistant to degradation. In contrast, peptides such as SV are more easily degraded by peptidase within an organism and show only a few adverse effects, such as oedema and pleural fluid accumulation. 18 -20 This indicates the high biocompatibility of peptides.
In this study, we hypothesized that the augmentation of myoblast sheets by SV gene transfer could improve cardiac function in the long term.
Methods

Animal ethics
Animal care complied with the 'Guide for Care and Use of Laboratory Animals' (NIH publication no. 85-23, revised 1996) . The Ethics Review Committee for Animal Experimentation of Osaka University Graduate School of Medicine approved the experimental protocols.
Isolation of skeletal myoblasts and sheets
After induction of general anaesthesia with pentobarbital (300 mg/kg) and heparin (150 U) by intraperitoneal injection, myoblasts were isolated from the skeletal muscle of the tibialis anterior muscle of 3-week-old male Lewis rats. The muscles were minced and enzymatically dissociated with 0.2% collagenase type II (Worthington Biochemical Corp., Lakewood, NJ, USA) and trypsin at 378C. The isolated cells were suspended in Dulbecco's modified Eagle's medium with 20% fetal bovine serum. After being preplated twice, non-adherent cells were then plated on a dish coated with Matrigel (Becton Dickinson Bioscience, Franklin Lakes, NJ, USA) and incubated at 378C in humidified air enriched with 5% CO 2 . We maintained the cell densities at ,70% confluence to prevent skeletal myoblast differentiation that would result in myotube formation. Myoblast sheets were formed by plating 3 × 10 6 infected myoblasts on a temperature-responsive culture dish (UpCell; CellSeed, Tokyo, Japan).
Animal model and myoblast sheet transplantation
The myocardial infarction (MI) models were generated via ligation of the left anterior descending (LAD) coronary artery in 8-week-old female F344/ NJcl-rnu/rnu rats. The rats were anaesthetized by inhalation of isoflurane (2%, 0.2 mL/min), intubated, and placed on a respirator during surgery to maintain ventilation. The carrier gas for isoflurane is oxygen. The adequacy of anaesthesia was monitored by electrocardiography and pulse rate. Two weeks after ligation of the LAD coronary artery, the myoblast sheets were transplanted. The rats were randomly divided into the following three groups: (i) a WT-rat skeletal myoblast (rSkM) group (transplanted with three wild-type myoblast sheets, n ¼ 6); (ii) an SV-rSkM group (transplanted with three SV-secreting myoblast sheets, n ¼ 8); and (iii) a control group (sham operation, n ¼ 6). Each sheet was individually applied to the infarcted area.
Overexpression and transfection of SV
A lentiviral vector containing the complementary DNA (cDNA) of SV (SV/ pCS-CG) was constructed ( Figure 1A ). The cDNA of SV was synthesized using DNA oligonucleotides. The primer sequences were as follows:
′ -TCGAGTTAAGCGTAATCTGGAACATCGTATGGGTACTCGA GCCTCAGTCCATAAACCACACT-3 ′ ; and reverse, 2,5 ′ -GGCCGGC TGGGCCGCGTCACCAGTGGAACCTGGAACCCAGAGCAGCAGTA CCCATAGCAGGAGTGTGTCTGTCTCCATGGTGGCG-3 ′ . The synthesized DNA oligonucleotides were linked and ligated to pCS-CG, and the isolated rSkMs were infected via incubation for 48 h in the presence of SV/pCS-CG.
Dot blotting assay
The culture media were used for the assays. Each sample was coated onto a black 96-well microplate overnight. To evaluate the secretion SV volume, the serially diluted solution of SV-HA peptide was also coated onto the plate as a control. After blocking, the primary antibody against the HA tag (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to each well. After washing, anti-rabbit IgG-linked horseradish peroxidase (GE Healthcare, Piscataway, NJ, USA) was added. After washing, the plate was exposed to an Enhanced Chemiluminescence (ECL) kit (GE Healthcare).
Measurement of cardiac function
The cardiac function of the treated rats was evaluated by echocardiography 2, 4, 6, and 8 weeks after sheet transplantation. Baseline measurements were Transplantation of SVVYGLR-secreting myoblast sheets made before sheet transplantation. The measurements were made using a SONOS 5500 sonograph (Philips Electronics, Tokyo, Japan) with a 12 MHz transducer under general anaesthesia induced and maintained by inhalation of isoflurane (2%, 0.2 mL/min) as mentioned above. The LV endsystolic area, LV end-diastolic area, and LV dimensions at end diastole and end systole (LVIDd and LVIDs, respectively) were determined. The ejection fraction (EF), fractional shortening (FS), end-diastolic volume (EDV), and end-systolic volume (ESV) were calculated as follows:
ESV ¼ LVIDs 3 × (1.14 × LVIDs + 4.18) (mL)
Heart weight/body weight ratio
The body weights (BW; in grams) of the rats were measured 8 weeks after sheet transplantation, after which the rats were anaesthetized with pentobarbital (300 mg/kg) and heparin (150 U) by intraperitoneal injection, and their hearts were rapidly removed and weighed (in milligrams). The heart weight (HW)/BW ratio was then calculated.
Histological analyses
Myocardial specimens were obtained 8 weeks post-transplantation. The formalin-fixed samples were embedded in paraffin. The LV chamber diameter and the anterior wall thickness were measured from sections stained with haematoxylin and eosin. Infarcted wall thickness, posterior wall thickness, and LV chamber diameter were measured with the scale loupe. The sections were evaluated morphologically using the NIS Elements system (Nikon, Tokyo, Japan). Sirius Red staining was used to detect fibrosis. The percentage of fibrosis was calculated from the fibrotic ratio in the infarct border area. Periodic acid-Schiff staining for cardiomyocyte hypertrophy was also performed. We randomly selected 100 cardiomyocytes and measured the two-point shortest axes at the level of the nucleus. Immunohistochemical staining for von Willebrand factor antigen was used to label vascular endothelial cells to permit the counting of blood vessels. The sections were incubated with primary antibody against von Willebrand factor (rabbit polyclonal; Dako, Glostrup, Denmark). The sections were incubated with a biotinylated anti-rabbit IgG antibody (Dako) and further incubated with peroxidase-conjugated streptavidin (SA; GE Healthcare). Visualization was performed with biphenyl-3,3 ′ ,4,4 ′ -tetramine solution (Sigma, St Louis, MO, USA). The stained vascular endothelial cells were counted under a light microscope.
The distribution of myofibroblast-like cells was evaluated by immunohistochemical staining with anti-smooth muscle actin (SMA) antibody (Dako) and anti-smooth muscle myosin heavy chain (SM-MHC) type 2 antibody (Abcam Ltd, Cambridge, UK). The SMA-positive cell density was calculated as SMA positive area/infarcted area × 100 (%).
Primary culture of adult ventricular fibroblasts
Cardiac fibroblasts (CFs) were isolated from 8-week-old adult male Sprague -Dawley rats 4 weeks after the induction of MI by LAD ligation. The hearts were excised from anaesthetized rats and quickly transferred to Hank's buffered salt solution. The minced left ventricular tissues were digested using 100 U/mL type II collagenase and 0.1% trypsin at 378C. The cells were centrifuged and suspended in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, and incubated at 378C in humidified air enriched with 5% CO 2 .
Immunofluorescence staining
The isolated fibroblasts were incubated with SV (10 mg/mL), SV random peptide (GYRVLSV; 10 mg/mL), or transforming growth factor-b1 (TGF-b1; 25 ng/mL) for 72 h. The cells were fixed with 4% paraformaldehyde and incubated with anti-SMA antibody followed by incubation with cyanine-3-conjugated anti-rabbit secondary antibody (GE Healthcare). The nuclei were stained with 4 ′ ,6-diamino-2-phenylindole (DAPI; Invitrogen Life Technologies, Grand Island, NY, USA), and the fluorescent signals were detected by fluorescence microscopy (ECLIPSE E600, Nikon).
Western blotting assay
The isolated fibroblasts were incubated with SV (10 mg/mL), SV random peptide (10 mg/mL), or TGF-b1 (25 ng/mL) for 72 h. The cells were suspended in lysis buffer (50 mM Tris at pH 8.0, 120 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40). Proteins in whole-cell lysates were separated by SDS -PAGE, transferred to a polyvinylidene fluoride transfer membrane (Millipore, Billerica, MA, USA), and probed sequentially with antibodies against SMA and a-tubulin (Sigma). The blots were developed using an ECL kit.
To examine the activity of TGF-b receptor -Smad signalling induced by SV, the phosphorylation of Smad2, Smad3, and TGF-b receptor I (TbRI) was studied by western blotting. The isolated fibroblasts were incubated with SV (10 mg/mL), SV random peptide (10 mg/mL), or TGF-b1 (25 ng/ mL) for 1 h. Primary antibodies against phospho-Smad2, phospho-Smad3, Smad2/3 (Cell Signaling Technology, Inc., Danvers, MA, USA), TbRI (phospho S165; Abcam), and a-tubulin were used.
Construction of recombinant transforming growth factor-b receptorII
A pcDNA3.1 vector containing the cDNA encoding TbRII (pcDNA3.1-TbRII) was constructed. The recombinant TbRII was produced by transfecting HEK 293T cells with pcDNA3.1-TbRII. The culture media containing recombinant TbRII were harvested. The purification of recombinant TbRII was done using immunoprecipitation with anti-TbRII antibody.
Biacore analysis
The binding of SV to TbRII was assessed by Biacore analysis. Biotinylated SVs were captured on SA-coated BIAcore SA sensor chips (GE Healthcare, Piscataway, NJ, USA). Ligands were diluted to 10 mg/mL and injected at 10 mL/mL. To correct for refractive index change, non-specific binding, and instrument drift, a reference flow cell contained the SA-coated surface only. The recombinant TbRII was diluted to 10 mg/mL in Hank's buffered salt solution and injected during the association phase for 5 min (30 mL/min).
In situ proximity ligation assay
The Duolink in situ proximity ligation assay (PLA; Olink Biosciences, Uppsala, Sweden) was performed according to the manufacturer's protocol. The isolated fibroblasts were incubated in the presence of SV-HA peptide or SV-HA random peptide (GYRVLSV; 1 mg/mL) for 1 h. The fixed fibroblasts were incubated with the following primary antibodies: rabbit polyclonal anti-TbRII (Abcam) and mouse monoclonal anti-HA (Nacalai Tesque). The cells were then incubated with PLA probes consisting of two secondary anti-rabbit and anti-mouse antibodies, each tagged with an oligonucleotide. A hybridization solution consisting of two oligonucleotide linkers complementary to each PLA probe was added to the cells. The isolated cells were incubated with a Duolink Ligation stock containing ligase and Duolink polymerase. In addition, the cells were incubated with a detection solution consisting of fluorescently labelled oligonucleotides that hybridize to the rolling circle amplification product. The PLA signal was visualized using fluorescence microscopy.
Statistical analyses
Data are presented as the means + SEM. Cardiac function was analysed by repeated-measures analysis of variance (ANOVA) for differences across the entire time course, as well as one-way ANOVA, whereas the Tukey -Kramer post hoc test was used to examine significant differences at each time point. To assess the significance of the differences between individual groups for A. Uchinaka et al.
other data, statistical comparisons were performed using Student's unpaired t-test. P , 0.05 was considered statistically significant.
Results
Overexpression of SV in rat skeletal myoblasts
The signal strength of dots in wells coated with the culture medium of SV/pCS-CG-infected rSkMs was stronger than that of dots in wells coated with the culture medium of mock-infected rSkMs ( Figure 1B[b] ). The SV was synthesized and secreted by SV/ pCS-CG-infected rSkMs. In addition, from the dilution series of SV-HA peptide, the secretion volume of SV was calculated to be approximately 3.125-6.25 ng/mL ( Figure 1B[a] ).
Effect of SV-secreting myoblast sheet on left ventricular function
Echocardiography revealed significantly better values of LVEF and %FS in the WT-rSkM and SV-rSkM groups compared with the control group at all time points after transplantation (P , 0.01). Although there were still significant differences between the control and WT-rSkM groups after the 4 week time point, the LVEF and %FS in the WT-rSkM group decreased dramatically. Furthermore, LVEF and %FS were significantly better in the SV-rSkM group at 2, 6, and 8 weeks after transplantation compared with the WT-rSkM group (2 and 6 weeks, P , 0.05; 8 weeks, P , 0.01; Figure 2A and B).
The
In particular, at 6 and 8 weeks after transplantation LVIDs was significantly attenuated in the SV-rSkM group compared with the control group (6 weeks P , 0.05; 8 weeks P , 0.01; Table 1 ). The enlargement of ESV was also significantly attenuated in the SV-rSkM group compared with the control group at 6 and 8 weeks after transplantation (6 weeks, P , 0.05; 8 weeks, P , 0.01; Table 1 ). The increase in EDV was significantly inhibited in the SV-rSkM group compared with the control group only at 8 weeks after transplantation (P , 0.05; Table 1 ).
Heart weight/body weight ratio
We used the HW/BW ratio as an indicator of cardiac hypertrophy. The HW/BW ratio was significantly greater in the SV-rSkM group at 8 weeks after transplantation compared with the control and WT-rSkM groups (P , 0.01; Figure 2C ).
Effect of SV-secreting myoblast sheet on left ventricular remodelling
Haematoxylin and eosin staining demonstrated thinning of the infarcted wall in the control and WT-rSkM groups, whereas the thickness of the infarcted wall was maintained in the SV-rSkM group ( Figure 2D and Table 2 ). Statistical analysis demonstrated that the LV chamber of the SV-rSkM group was significantly less dilated that those of the control and WT-rSkM groups (P , 0.05; Table 2 ) and that the infarcted wall in the SV-rSkM group was significantly thicker than that in the control Transplantation of SVVYGLR-secreting myoblast sheets and WT-rSkM groups (P , 0.01; Table 2 ). The values of the LV chamber diameter/posterior wall thickness were significantly lower in the SV-rSkM group compared with those in the control and WT-rSkM groups (P , 0.01; Table 2 ). There were no significant differences between the control and WT-rSkM groups regarding these indices. The SV-rSkM group exhibited a significantly lower percentage of fibrosis than the control and WT-rSkM groups in the infarcted border area (P , 0.01; Figure 3A) . The diameters of cardiomyocytes in the SV-rSkM group were significantly smaller than those in the control and WT-rSkM groups (P , 0.01; Figure 3B ). There was no significant difference in the area remote from the transplant among the three groups.
The pro-angiogenic effects of SV
The capillary density 8 weeks after transplantation was significantly higher in the WT-rSkM and SV-rSkM groups than in the control group (P , 0.01). Furthermore, the capillary density in the SV-rSkM group was significantly higher than that in the WT-rSkM group (P , 0.01; Figure 3C [a]-C[c] and D). There was no significant difference in the area remote from the transplant among the three groups.
The accumulation of smooth muscle actin-positive and smooth muscle myosin heavy chain type2-positive cells by SV
Immunohistochemical staining with an anti-SMA antibody revealed that many clusters of SMA-positive cells were present in infarcted areas in the SV-rSkM group ( Figure 3E ). Statistical analysis indicated that the SMApositive cell density was significantly higher in the WT-rSkM and SV-rSkM groups than in the control group (WT-rSkM , P , 0.05; SV-rSkM, P , 0.01; Figure 3F) . Furthermore, the SMA-positive cell density was significantly higher in the SV-rSkM group than in the WT-rSkM group (P , 0.05; Figure 3F) . Notably, SM-MHC type 2-positive cells were also detected in infarcted areas in the SV-rSkM group, whereas those cells were scarce in the control and WT-rSkM groups ( Figure 3G ).
The induction of smooth muscle actin by SV
Expression of SMA was increased when SV was added to the isolated fibroblasts ( Figure 4A and B) . The expression level of SMA was similar to that of TGF-b1 ( Figure 4B ). Conversely, the expression level of SMA was unchanged by the addition of SV random peptide ( Figure 4A  and B) . 
Binding of SV to transforming growth factor-b receptor II
When PLA was performed using rabbit polyclonal anti-TbRII and mouse monoclonal anti-HA antibodies for the isolated fibroblasts treated with SV-HA peptide, PLA-positive red signals were found ( Figure 4C[a] ). In contrast, PLA-positive red signals were not detected in the isolated fibroblasts treated with SV-HA random peptide ( Figure 4C[b] ). We assessed the ability of SV to bind to TbRII, using a sensor chip immobilized with biotinylated SV (K D ¼ 13.5 nM), and this peptide bound to TbRII with high affinity (500 Resonance Unit; Figure 4D ). However, SV random peptides (K D ¼ 16 nM) had a much lower R max (R max ¼ analyte molecular weight (MW)/ligand MW × the immobilization level × the stoichiometric ratio) value (200 Resonance Unit).
The effects of SV on Smad activation
Treatment with TGF-b1 or SV induced the phosphorylation of TbRI, Smad2, and Smad3 to similar degrees ( Figure 4E) . Conversely, treatment with SV random peptide had no effect on TbRI, Smad2, and Smad3 phosphorylation.
Discussion
In this study, we transplanted myoblast sheets to the myocardium in an infarcted rat model. The cell sheets are removed from special temperature-responsive dishes without destroying the cell -cell or cell -extracellular matrix adhesions in the cell sheet. The myoblast sheet does not require an artificial scaffold, because it has a great ability to integrate with the infarcted area via an adhesion factor, such as integrin-a 7 b 1 and a-dystroglycan, which are expressed on the surface of myoblasts; thus, the sheets do not fall off after the chest is closed. 5 -7 The effect of myoblast sheet transplantation is mediated mainly by paracrine growth factors that stimulate the injured myocardium. 6, 7 The paracrine effectors include HGF, VEGF, and stromal-derived factor 1. These factors can promote angiogenesis in the ischaemic myocardium. Hepatocyte growth factor is also associated with anti-fibrosis and anti-apoptosis. The grafted myoblasts beneficially attract haematopoietic stem cells to home in on the infarcted heart area for heart regeneration and angiogenesis by stromal-derived factor 1. 6 These paracrine activities induce angiogenesis and reduce fibrosis and hypertrophy; as a result, the depressed cardiac function improves. Therefore, we hypothesized that functional modification of myoblast sheet properties by overexpressing a factor associated with angiogenesis, anti-fibrosis, and anti-apoptosis could further promote and maintain the therapeutic effects of the sheet. Our previous results demonstrated that SV has a much stronger pro-angiogenic action than VEGF. 14 Given that SV has a straight-chain sequence, rather than a complicated conformation, we can speculate that this peptide would be degraded by peptidase within an organism. Our previous research has shown that synthetic SV has no effect on the proliferation of endothelial and muscle cells. 13, 14 The degradation rate and function for the proliferation of SV could have high biocompatibility with peptides. In this study, we investigated the effects of SV-secreting myoblast sheets in infarcted rat hearts. Most of the transplanted myoblasts drop out at 4 weeks after sheet transplantation. 21 As a result, cardiac function in the WT-rSkM group at 4 weeks after sheet transplantation was markedly decreased. In contrast, in the SV-rSkM group the functional improvements were maintained for 8 weeks after sheet transplantation. The capillary density 8 weeks after transplantation was significantly higher in the SV-rSkM group than in the control and WT-rSkM groups. The vessels newly formed by the secreted SVs from the myoblast sheets remained until 8 weeks post-transplantation, after the drop-out of the transplanted cells. The paracrine factors from transplanted myoblasts also promoted angiogenesis. Thus, in this study, the secreted SV showed an enhanced angiogenic action after myoblast transplantation. It is possible that SV induced angiogenesis in both the surviving cardiomyocytes and the transplanted cells; as a result, the survival time of the transplanted cells would have been extended. However, there are no data concerning the effect of SV-rSkM on the endogenous mobilization/proliferation/apoptosis and differentiation of cardiac resident cardiac stem/progenitor cells. More research is needed to define the effects of SV on these cells. Siltanen et al. 11 reported the efficacy of a heart failure treatment involving the transplantation of myoblasts genetically modified to overexpress HGF. Hepatocyte growth factor is a cardioprotective factor associated with angiogenesis, anti-fibrosis, and anti-apoptosis. 22, 23 Hepatocyte growth factor-overexpressing myoblast sheets stimulated angiogenesis and inhibited myocardial fibrosis in a rat chronic heart failure model. However, cardiac function was not improved by the transplantation of HGF-overexpressing sheets. 16 In contrast, SV-expressing sheets, which also have a pro-angiogenic action, enhanced cardiac function and angiogenesis. Transplantation of SV-secreting sheets enhanced the functional recovery of ischaemic myocardium compared with the findings in the control and WT-rSkM groups. In particular, systolic parameters, such as LVIDs and ESV, were significantly improved in the SV-rSkM group. Myofibroblasts share morphological features with fibroblasts and smooth muscle cells. Differentiated myofibroblasts are characterized by increased a-SMA and the morphological features of well-developed stress fibres. 24 Although myofibroblasts in normal tissue, granulation tissue, and pathological tissue exhibit phenotypic a-SMA expression, SM-MHC, vimentin, and desmin, myofibroblasts more commonly express a-SMA. 25 Myofibroblasts have a greater contractile capability than undifferentiated CFs, and this property is believed to be important in maintaining the structural integrity of healing scars. 26 Expression of a-SMA in stress fibres is instrumental in force generation by myofibroblasts. 27 Additionally, myofibroblasts confer mechanical tension to remodelling matrix via anchoring and contracting. 24 In this study, many clusters of SMA-positive and SM-MHC type 2-positive cells were observed in infarcted areas in the SV-rSkM group. These cells differentiated from CFs into myofibroblasts in the infarcted area after the addition of SV, and the myocardial contractile performance of the infarcted wall in the SV-rSkM group was improved by the accumulation of myofibroblasts. Our previous study indicated that, when skeletal myoblast sheets were transplanted into a swine acute MI model, welldeveloped smooth muscle cells accumulated in the centre of the scar. 28 In our study, more SMA-positive cells accumulated in the infarcted area in the SV-rSkM group than in the WT-rSkM-group, and the secreted SV enhanced the effect of SMA expression by CFs. Furthermore, owing to the accumulation of myofibroblasts in the infarcted area, adverse effects on the uninjured myocardium and its exercise endurance were decreased; consequently, cardiac remodelling processes, such as fibrosis and cardiomyocyte hypertrophy, were attenuated. The fibroblasts in scar tissue of the infarcted area are differentiated into SMApositive and SM-MHC type 2-positive cells by SV. There is no cell -cell connectivity between these cells and the recipient's cardiomyocytes, and it is possible that they have not been synchronized with the cardiomyocytes. However, they do have a contractile capability, and SV could have transferred the contractility to the infarcted wall via the accumulation of these cells, improving the motion of the scared left ventricular wall and inhibiting the dilatation of the LV chamber in the SV-rSkM group. Our previous research has shown that synthetic SVVYGLR peptides in vitro activate the adhesion and migration of endothelial cells and smooth muscle cells, and stimulate tube formation by vascular endothelial cells. 13, 14 In contrast, SV has no effect on the proliferation of these cells, whereas it enhances the adhesion and proliferation of several types of human mesenchymal cells. 17 Although the effects of SV on apoptosis in these cells have not been evaluated, the results regarding proliferation suggest that SV has no effect on apoptosis. According to these data, SV should have no impact on the proliferation and apoptosis of myoblasts, while stimulating the proliferation of fibroblasts and myofibroblasts. Osteopontin is highly expressed during the differentiation of fibroblasts into myofibroblasts, and could have an effect on fibroblast differentiation and a role in myofibroblast function during tissue remodelling. 29 Transforming growth factor-b plays an important role in the activation of fibroblasts in wound repair, and it induces myofibroblast differentiation via Smad signalling. 30 Osteopontin is required for the differentiation and activation of myofibroblasts formed in response to TGF-b1. 31 This study illustrated that, in isolated CFs, SV had a great degree of affinity for TbRII and activated Smad signalling via TbRs. The secreted SV bound TbRII and induced the differentiation of fibroblasts into myofibroblasts through TGF-b receptor-Smad signalling.
Transforming growth factor-b participates in vascular development and the maintenance of vascular homeostasis, and it induces angiogenesis at low levels. 32 Transforming growth factor-b regulates angiogenesis by acting on both vascular endothelial and smooth muscle cells. 31 SV also stimulates angiogenesis at low levels, but this effect plateaus at high levels. 14 Thus, SV induces angiogenesis via the same mechanism as TGF-b. However, we believed that SV could also bind receptors other than TbRII and exhibit myocardium-protecting actions, such as promoting angiogenesis and inhibiting hypertrophy. To explain the effect of SV in improving cardiac function, SV receptors in myocardial tissue will have to be identified, and the details of its mechanism will need to be examined. Functional SV peptide-secreting myoblast sheets facilitate long-term improvement in cardiac function and inhibition of cardiac remodelling. The SVs secreted from myoblast sheets effectively stimulated angiogenesis in the failing myocardium. The accumulation of SMA-positive cells induced by SV confers a contractile property on the infarcted wall. The early therapeutic effects after SV-secreting myoblast sheet transplantation were due to the paracrine effects of the transplanted myoblasts, and the late effects were caused by the pro-angiogenic effects of SV and its induction of myofibroblast accumulation via TGF-bSmad signalling. These results suggest that SV could change CFs to muscle-like cells, allowing it to be used as a bridge to heart transplantation or as an ideal peptide drug for cardiac regeneration therapy.
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